Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Research & Development (2017 - 2025)

Organogenesis Holdings (ORGO) has 9 years of Research & Development data on record, last reported at $10.3 million in Q4 2025.

  • For Q4 2025, Research & Development fell 10.79% year-over-year to $10.3 million; the TTM value through Dec 2025 reached $44.5 million, down 11.4%, while the annual FY2025 figure was $44.5 million, 11.4% down from the prior year.
  • Research & Development reached $10.3 million in Q4 2025 per ORGO's latest filing, down from $13.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $15.6 million in Q2 2024 and bottomed at $6.2 million in Q1 2021.
  • Average Research & Development over 5 years is $10.5 million, with a median of $10.4 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 141.39% in 2021, then tumbled 33.31% in 2025.
  • A 5-year view of Research & Development shows it stood at $8.3 million in 2021, then soared by 37.95% to $11.4 million in 2022, then rose by 3.29% to $11.8 million in 2023, then fell by 2.04% to $11.5 million in 2024, then fell by 10.79% to $10.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $10.3 million in Q4 2025, $13.2 million in Q3 2025, and $10.4 million in Q2 2025.